
GSK, Hengrui Focus on Cancer, Respiratory Diseases, I&I in Up-to-$12.5B Collaboration
GlaxoSmithKline (GSK) will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology, and inflammation (RI&I) as well as oncology, through a collaboration that could generate up to $12.5 billion-plus for the …